Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2003

View Archived Issues

Treatment begins in INGN-225 phase I/II study

rhIGF-I/rhIGFBP-3 enters phase III trial for GHIS

Two series of PDF inhibitors claimed by De Novo scientists

Actelion presents new urotensin-II antagonists for hypertension, atherosclerosis, angina, etc.

Schering researchers prepare and test novel MCH antagonists

New adenosine A1 and/or A3 receptor antagonists under study at OSI

Korean researchers identify novel sPLA2 inhibitors

New Src/MEK kinase inhibitors in early development at AstraZeneca

New trials advance CeNeS pain programs

Connetics submits NDA for Extina in seborrheic dermatitis

Pivotal trial assesses Focalin LA in adults with ADD/ADHD

CA4P evaluated for potential in wet AMD

SAHA enters phase I trial in advanced leukemias

Neurochem clinical advisory board recommends initiation of phase III for Alzhemed

NS-2359 phase I program for ADHD successfully completed

Emtriva approved by FDA for treatment of HIV

Phase I trial initiated for MLN-944

Approval sought for Plenaxis in Germany

British Biotech reviews past year's operations

Fungal metabolites acting on the fungal cell wall discovered by Schering-Plough

Age-related cognitive decline reversed by Eukarion SOD/catalase mimetics

Aricept deemed not approvable for vascular dementia

Water-soluble prodrug of maxi-K channel opener as potential poststroke therapy

APT-070 now holds orphan drug status in transplantation on two continents

Minimal VEGF exon 6-encoded sequence with antiangiogenic activity identified

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...